Open AccessVedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report
Author(s) -
Manreet Randhawa,
Gregory Gaughran,
Christine Archer,
Paul Pavli,
Adrienne Morey,
Sayed Ali,
Desmond Yip
Publication year - 2019
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v10.i10.350
Subject(s) - vedolizumab , medicine , ipilimumab , infliximab , nivolumab , refractory (planetary science) , ulcerative colitis , colitis , gastroenterology , oncology , immunotherapy , immunology , cancer , tumor necrosis factor alpha , disease , physics , astrobiology
Dual checkpoint inhibition improves response rates in treatment naïve patients with metastatic melanoma compared to monotherapy. However, it confers a higher rate of toxicity, including immune-related colitis. Steroids may not resolve symptoms in all cases. The use of vedolizumab, a humanized monoclonal antibody against α4β7 integrin has proven effective in cases refractory to standard treatment.